Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

D. R. Spigel; T. J. Ervin; R. Ramlau; D. B. Daniel; J. H. Goldschmidt; G. R. Blumenschein; M. J. Krzakowski; G. Robinet; C. Clement-Duchene; F. Barlesi; R. Govindan; T. Patel; S. V. Orlov; M. S. Wertheim; J. Zha; A. Pandita; W. Yu; R. L. Yauch; P. H. Patel; A. C. Peterson

doi:10.1200/JCO.2011.29.15_SUPPL.7505

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

D. R. Spigel
, T. J. Ervin
, R. Ramlau
, D. B. Daniel
, J. H. Goldschmidt
, G. R. Blumenschein
, M. J. Krzakowski
, G. Robinet
, C. Clement-Duchene
, F. Barlesi
, R. Govindan
, T. Patel
, S. V. Orlov
, M. S. Wertheim
, J. Zha
, A. Pandita
, W. Yu
, R. L. Yauch
, P. H. Patel
, A. C. Peterson

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	29
DOIs	https://doi.org/10.1200/JCO.2011.29.15_SUPPL.7505
State	Published - May 20 2011

Disciplines

Medicine and Health Sciences
Oncology
Surgery
Internal Medicine

Access to Document

10.1200/JCO.2011.29.15_SUPPL.7505License: Unspecified

Cite this

Spigel, D. R., Ervin, T. J., Ramlau, R., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Clement-Duchene, C., Barlesi, F., Govindan, R., Patel, T., Orlov, S. V., Wertheim, M. S., Zha, J., Pandita, A., Yu, W., Yauch, R. L., Patel, P. H., & Peterson, A. C. (2011). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology, 29. https://doi.org/10.1200/JCO.2011.29.15_SUPPL.7505

Spigel, DR, Ervin, TJ, Ramlau, R, Daniel, DB, Goldschmidt, JH, Blumenschein, GR, Krzakowski, MJ, Robinet, G, Clement-Duchene, C, Barlesi, F, Govindan, R, Patel, T, Orlov, SV, Wertheim, MS, Zha, J, Pandita, A, Yu, W, Yauch, RL, Patel, PH & Peterson, AC 2011, 'Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.', Journal of Clinical Oncology, vol. 29. https://doi.org/10.1200/JCO.2011.29.15_SUPPL.7505

@article{e9e07827153d40448b7f58716c87ff16,

title = "Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.",

author = "Spigel, \{D. R.\} and Ervin, \{T. J.\} and R. Ramlau and Daniel, \{D. B.\} and Goldschmidt, \{J. H.\} and Blumenschein, \{G. R.\} and Krzakowski, \{M. J.\} and G. Robinet and C. Clement-Duchene and F. Barlesi and R. Govindan and T. Patel and Orlov, \{S. V.\} and Wertheim, \{M. S.\} and J. Zha and A. Pandita and W. Yu and Yauch, \{R. L.\} and Patel, \{P. H.\} and Peterson, \{A. C.\}",

note = "7505 Background: Met is associated with a poor outcome in many cancers, including NSCLC. Met activation is a mechanism of resistance to EGFR inhibition, supporting dual inhibition of Met/EGFR. MetMAb is a monovalent monoclonal antibody that specifically binds the Met receptor.",

year = "2011",

month = may,

day = "20",

doi = "10.1200/JCO.2011.29.15\_SUPPL.7505",

language = "American English",

volume = "29",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

AU - Spigel, D. R.

AU - Ervin, T. J.

AU - Ramlau, R.

AU - Daniel, D. B.

AU - Goldschmidt, J. H.

AU - Blumenschein, G. R.

AU - Krzakowski, M. J.

AU - Robinet, G.

AU - Clement-Duchene, C.

AU - Barlesi, F.

AU - Govindan, R.

AU - Patel, T.

AU - Orlov, S. V.

AU - Wertheim, M. S.

AU - Zha, J.

AU - Pandita, A.

AU - Yu, W.

AU - Yauch, R. L.

AU - Patel, P. H.

AU - Peterson, A. C.

N1 - 7505 Background: Met is associated with a poor outcome in many cancers, including NSCLC. Met activation is a mechanism of resistance to EGFR inhibition, supporting dual inhibition of Met/EGFR. MetMAb is a monovalent monoclonal antibody that specifically binds the Met receptor.

PY - 2011/5/20

Y1 - 2011/5/20

UR - https://ascopubs.org/doi/10.1200/jco.2011.29.15_suppl.7505

U2 - 10.1200/JCO.2011.29.15_SUPPL.7505

DO - 10.1200/JCO.2011.29.15_SUPPL.7505

M3 - Article

VL - 29

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

Disciplines

Access to Document

Other files and links

Cite this